In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Adherence to therapy based on core cognitive domains in patients with coronary artery disease

Session Poster session 1

Speaker Olga Maleva

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : O Maleva (Kemerovo,RU), O Trubnikova (Kemerovo,RU), T Kupriyanova (Kemerovo,RU), O Barbarash (Kemerovo,RU)

O. Maleva1 , O. Trubnikova1 , T. Kupriyanova1 , O. Barbarash1 , 1Research Institute for Complex Issues of Cardiovascular Diseases - Kemerovo - Russian Federation ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 183

Purpose: To evaluate the relationship between adherence to therapy and core cognitive domains in patients with coronary artery disease (CAD).

Material and methods: The relationship between therapy and specific cognitive domains has been analyzed in 188 male patients with stable coronary artery disease (the mean age 57±5.7 years). The 1-year adherence to therapy included the assessment of regular reception of β-blockers, statins, antiplatelet agents (aspirin), angiotensin converting enzyme inhibitors and the achievement of target blood pressure levels, total cholesterol, high and low density lipoproteins, triglycerides, heart rate, and weight loss. The assessment of cognitive status was performed using an automated complex software “Status-PF”. The integrated algorithms allowed to assess core cognitive domains: executive function (complex visual-motor reaction time, functional mobility of nervous processes, the force of the nervous processes, the number of errors and missed signals during their processing); visuospatial ability (the Burdon's test with the calculation of the number of processed symbols in 1 and 4 minutes); and recent memory (10 words memorizing test, 10 numbers memorizing test, 10 nonsense syllables test). The statistical analysis was performed using the software “SPSS” with the calculation of weighted coefficient for adherence to therapy (w). The correlation analysis was performed using the software “STATISTICA 8.0”.

Results: A regular reception of β-blockers was associated with preserved recent memory (w = 0.687, p=0.0015), visuospatial ability (w = 0.204, p=0.05) and executive function (w = 0.639, p=0.03). A regular intake of antiplatelet agents significantly contributed to the preservation of recent memory (w = 0.141, p=0.0073) and visuospatial ability (w = 0.232, p=0.04). A regular statins reception was associated with preserved recent memory (w = 0.172, p=0.006). A correlation between the integral index of cognitive status and patients' adherence to treatment has been determined (r = + 0.36, p=0.04). Positive associations between the integral index and recent memory (r = + 0.36, p=0.03), visuospatial ability (r = + 0.21, p=0.04), and executive function (r = + 0.36, p=0.04) have been identified.

Conclusion: There are positive relationships between patients' adherence to therapy and recent memory, visuospatial ability and executive function in patients with CAD. These relationships should be considered while supervising patients with coronary artery disease, as well as finding effective approaches for their motivation to improve their adherence to medical regimen.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are